niacin has been researched along with Peripheral Arterial Disease in 8 studies
Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.
vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).
nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.
Peripheral Arterial Disease: Lack of perfusion in the EXTREMITIES resulting from atherosclerosis. It is characterized by INTERMITTENT CLAUDICATION, and an ANKLE BRACHIAL INDEX of 0.9 or less.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with PAD on ASA therapy at baseline were included from the ongoing Effect of Lipid Modification on Peripheral Arterial Disease after Endovascular Intervention Trial (ELIMIT), which is a randomized trial testing whether combination treatment with ezetimibe, niacin, and a statin will halt/regress atherosclerosis compared with statin monotherapy." | 9.15 | Variability and persistence of aspirin response in lower extremity peripheral arterial disease patients. ( Ballantyne, CM; Dong, JF; Kimball, KT; Lumsden, AB; Morrisett, JD; Nambi, V; Saunders, J; Virani, SS, 2011) |
| "Patients with PAD on ASA therapy at baseline were included from the ongoing Effect of Lipid Modification on Peripheral Arterial Disease after Endovascular Intervention Trial (ELIMIT), which is a randomized trial testing whether combination treatment with ezetimibe, niacin, and a statin will halt/regress atherosclerosis compared with statin monotherapy." | 5.15 | Variability and persistence of aspirin response in lower extremity peripheral arterial disease patients. ( Ballantyne, CM; Dong, JF; Kimball, KT; Lumsden, AB; Morrisett, JD; Nambi, V; Saunders, J; Virani, SS, 2011) |
| " The Intermittent Claudication Proof of Principle (ICPOP) study tested the hypothesis that the combination of extended release niacin plus lovastatin would improve exercise performance in patients with PAD and claudication compared with a diet intervention." | 5.14 | Effect of niacin ER/lovastatin on claudication symptoms in patients with peripheral artery disease. ( Ballantyne, CM; Creager, MA; Dale, RA; Hiatt, WR; Hirsch, AT; Mohler, ER; Rajagopalan, S; Regensteiner, JG; Rooke, T; Treat-Jacobson, D, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Katsiki, N | 1 |
| Giannoukas, AD | 1 |
| Athyros, VG | 1 |
| Mikhailidis, DP | 1 |
| Brunner, G | 1 |
| Yang, EY | 1 |
| Kumar, A | 1 |
| Sun, W | 1 |
| Virani, SS | 2 |
| Negi, SI | 1 |
| Murray, T | 1 |
| Lin, PH | 1 |
| Hoogeveen, RC | 1 |
| Chen, C | 1 |
| Dong, JF | 2 |
| Kougias, P | 1 |
| Taylor, A | 1 |
| Lumsden, AB | 2 |
| Nambi, V | 2 |
| Ballantyne, CM | 3 |
| Morrisett, JD | 2 |
| Hiatt, WR | 1 |
| Hirsch, AT | 1 |
| Creager, MA | 1 |
| Rajagopalan, S | 1 |
| Mohler, ER | 1 |
| Regensteiner, JG | 1 |
| Treat-Jacobson, D | 1 |
| Dale, RA | 1 |
| Rooke, T | 1 |
| Saunders, J | 1 |
| Kimball, KT | 1 |
| DEWITZ, A | 1 |
| GOLDBERG, S | 1 |
| BRANZI, G | 1 |
| ANNINO, G | 1 |
| MAZZEO, F | 1 |
| SPAMPINATO, N | 1 |
| CORSALE, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| "Effect of Lipid Modification on Peripheral Arterial Disease After Endovascular Intervention (The ELIMIT Trial)"[NCT00687076] | Phase 4 | 102 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
| Effect of Niacin ER/Lovastatin on Peak Walking Time and Claudication Onset Time in Patients With Intermittent Claudication[NCT00062556] | Phase 3 | 366 participants | Interventional | 2003-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Lipids: Total cholesterol (mg/dl); Lipid Data at 12-Months (change from baseline) [mg/dl]. (NCT00687076)
Timeframe: Measured at baseline and 12 months
| Intervention | mg/dl (Median) |
|---|---|
| Triple Therapy | -30.0 |
| Mono Therapy | -7.5 |
"The primary outcome variable was the change in superficial femoral artery (SFA) wall volume over 24-months, as determined by MRI. The 24-month changes in SFA lumen and SFA total vessel volumes were also analyzed.~Analysis details: A total of 102 patients were randomized. 87 patients completed baseline MRI. Between randomization and the baseline visit, 1 patient withdrew from the study, 8 patients opted out from baseline imaging, and 6 additional patients declined blood collection at baseline. The multilevel models (primary endpoint) used all available imaging data (n=91), including patients who only completed baseline imaging (n=20) or completed at least 2 imaging visits other than baseline (n=4)." (NCT00687076)
Timeframe: Measured at baseline and 24 Months
| Intervention | mm^3, at 24-months (Mean) |
|---|---|
| Triple Therapy | 58.1 |
| Mono Therapy | 60.5 |
1 review available for niacin and Peripheral Arterial Disease
| Article | Year |
|---|---|
Lipid-lowering treatment in peripheral artery disease.
Topics: Animals; Cholesterol Ester Transfer Proteins; Ezetimibe; Fibric Acids; Humans; Hypolipidemic Agents; | 2018 |
3 trials available for niacin and Peripheral Arterial Disease
| Article | Year |
|---|---|
The Effect of Lipid Modification on Peripheral Artery Disease after Endovascular Intervention Trial (ELIMIT).
Topics: Aged; Azetidines; Cholesterol; Double-Blind Method; Endothelium, Vascular; Ezetimibe; Female; Femora | 2013 |
Effect of niacin ER/lovastatin on claudication symptoms in patients with peripheral artery disease.
Topics: Aged; Delayed-Action Preparations; Drug Therapy, Combination; Exercise Test; Female; Humans; Hydroxy | 2010 |
Variability and persistence of aspirin response in lower extremity peripheral arterial disease patients.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon; Arachidonic Acid; Aspir | 2011 |
4 other studies available for niacin and Peripheral Arterial Disease
| Article | Year |
|---|---|
[Policlinical contribution to the treatment of peripheral arterial circulation disorders].
Topics: Bile Acids and Salts; Niacin; Nicotinic Acids; Peripheral Arterial Disease; Peripheral Vascular Dise | 1957 |
[Magnesium compositum-a new medication for the treatment of peripheral arterial circulatory disorders].
Topics: Humans; Magnesium; Niacin; Nicotinic Acids; Peripheral Arterial Disease; Peripheral Vascular Disease | 1963 |
[Therapy of peripheral arteriopathies with a compound with a base of inositol hexanicotinate].
Topics: Inositol; Niacin; Nicotinic Acids; Peripheral Arterial Disease; Peripheral Vascular Diseases; Pyrido | 1963 |
[3-(METHYLHYDROXYETHYLAMINO)-2-HYDROXYPROPYLTHEOPHYLLINE NICOTINATE IN THE TREATMENT OF PERIPHERAL ARTERIOPATHIES].
Topics: Angiography; Drug Therapy; Geriatrics; Humans; Niacin; Nicotinic Acids; Peripheral Arterial Disease; | 1964 |